Skip to main content
. 2011 Apr;36(4):197–202.

Table 3.

Comparison of Sipuleucel-T (Provenge) and Docetaxel (Taxotere) in Quality of Life

Sipuleucel-T Docetaxel
Treatment period 1 month 7 months
Common adverse events Fever and chills for 3 days Hair loss
Percentage of patients hospitalized for adverse events 1.2% >26%
Percentage of patients stopping treatment because of adverse events 1% 11%
Percentage of patients dying owing to adverse events None 1% to 3%

From Provenge prescribing information;15 Force R, et al. Cancer Res 2009;69(24Suppl 3);19 Berthold DR, et al. J Clin Oncol 2008;26:242–245;20 and Miller D, July 29, 2010.21